<?xml version="1.0" encoding="ISO-8859-1"?>
<?xml-stylesheet type="text/xsl" href="helma.xsl"?>
<xmlroot xmlns:hop="http://www.helma.org/docs/guide/features/database">
  <hopobject id="2432" name="Page" prototype="Page" created="1363280116832" lastModified="1542952436824">
  <hop:parent idref="0" prototyperef="Root"/>
    <http_browser>Mozilla/4.0 (compatible; MSIE 6.0; Windows NT 5.1; SV1)</http_browser>
    <lang>en-us</lang>
    <uri>bone-update</uri>
    <http_host>127.0.0.1:8080</http_host>
    <time type="date">23.11.2018 05:53:56 UTC</time>
    <pseudoparent idref="0" prototyperef="Root"/>
    <http_remotehost>127.0.0.1</http_remotehost>
    <hopsession>127.0.0.r6h1p0osks0v</hopsession>
    <user>default</user>
    <pvcount type="float">85.0</pvcount>
    <body>Would you like a receipt? &lt;a href=&quot;http://www.infocalcbba.edu.bo/genericcialcom-9e88.pdf&quot;&gt;mba-health-care.de&lt;/a&gt;  The Phase III trial compared Yervoy (ipilimumab) to placebo following radiation in patients with advanced metastatic castration-resistant prostate cancer (mCRPC) who have received prior treatment with docetaxel. The 799-patient study&amp;rsquo;s primary endpoint of overall survival did not reach statistical significance (11.2 months versus 10 months for placebo) but anti-tumour activity &amp;ldquo;was observed across some efficacy endpoints, including progression free-survival&amp;rdquo;, B-MS noted. More data will be presented at the European Cancer Congress in Amsterdam at the end of the month.
 </body>
    <http_language>en-US,en;q=0.8</http_language>
    <is_xhtml type="boolean">true</is_xhtml>
    <http_referer>http://beagleboard.org/bone-update/edit</http_referer>
  </hopobject>
</xmlroot>
